Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.81 +1.03%

+$0.06 today

Market cap
$1.34B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 9.92M

Average 4.07M

Returns on capital

Nuvation Bio Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-66.9%

avg -18.0%

ROIC

-41.0%

avg 54.1%

ROA

-34.4%

avg -106.6%

Analysis

ROA is currently the strongest return metric at -34.4% versus its period average of -106.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David T. Hung

Founder, President, Chief Executive Officer & ChairmanUSD 1.2M68——

Philippe Sauvage

Chief Financial Officer & Principal Financial OfficerUSD 810.02K4854.13K0.02%

Gary Hattersley

Chief Scientific OfficerUSD 805.8K590<0.01%

Colleen Sjogren

Chief Commercial OfficerUSD 615.84K55748.13K0.22%

David C. Hanley

Chief Technical Operations OfficerUSD 586.04K56748.13K0.22%

Moses Makunje

Vice President of Finance and Principal Accounting & Financial Officer—4768.14K0.02%

Robert DeVita

Vice President of Corporate Development & Investor Relations————

Kerry A. Wentworth

Chief Regulatory Officer—53——

Stacy Markel

Chief People Officer—6132.59K<0.01%

Stephen Dang

Chief Legal Officer & Corporate Secretary————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 19, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$118,250.00

Sells

14

$8.61M

Net Transaction Value

−$8.49M

Net selling

Most Active

Liu Dongfang

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 19, 26

Hattersley Gary

Direct

Sell$709.2K
Jun 23, 26

Markel Stacy

Direct

Sell$753.2K
Jun 23, 26

Wentworth Kerry

Direct

Sell$379.2K
Jun 23, 26

Sauvage Philippe

Direct

Sell$286.4K
Jun 9, 26

Mashal Robert

Indirect

Buy$118.3K
Apr 17, 26

Wentworth Kerry

Direct

Sell$184.3K
Apr 17, 26

Liu Dongfang

Direct

Sell$251K
Apr 6, 26

Wentworth Kerry

Direct

Sell$903.6K
Dec 1, 25

Liu Dongfang

Direct

Sell$1.2M
Nov 26, 25

Liu Dongfang

Direct

Sell$80K

1–10 of 15

Summary

Insiders reported 1 buys worth $118,250.00 and 14 sells worth $8.61M over the last 12 months. That adds up to net selling of $8.49M. Liu Dongfang was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
+64.1% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +64.1% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Nuvation Bio Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NUVB's management, answered from reported figures.

Who manages NUVB?

Nuvation Bio Inc. (NUVB) lists 10 active executives. The top listed executive is David C. Hanley, Chief Technical Operations Officer.

Are NUVB insiders buying or selling?

Recent insider activity shows net buying of $114.79M.